Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms

被引:0
|
作者
Deng Bo [1 ]
Jia Liqun [1 ]
Tan Huangying [1 ]
Lou Yanni [1 ]
Li Xue [1 ]
Li Yuan [1 ]
Yu Lili [1 ]
机构
[1] China Japan Friendship Hosp, Integrat Oncol Dept, Beijing 100029, Peoples R China
关键词
UGT1A1; enzyme; Diarrhea; Irinotecan; Shengjiangxiexin decoction; COLORECTAL-CANCER PATIENTS; INDUCED DIARRHEA; OXALIPLATIN; UGT1A;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To evaluate the efficacy of Shengjiangxiexin decoction (SXD), prepared with a formula from Traditional Chinese Medicine (TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase (UGT)1A1*28 and UGT1A1*6 polymorphisms. METHODS: This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus 1-leucovorin (FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to 6 day post chemotherapy. Chemotherapy induced adverse reactions (neutropenia, diarrhea, nausea, vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." RESULTS: A total of 50 patients had *1/*1 wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had two alleles variants with genotype *6/*6, *28/*28 or *61* 28. In *1/*6 or *1/*28 patients (high risk group),.9 patients (15.5%) developed I II grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients (32.8%) and only 3 patients (8.6%) developed sever neutropenia. There were no significant differences in any toxic effects (neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients (high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients (*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28 polymorphisms and clinical response of chemotherapy. CONCLUSION: SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients (high risk group), while this treatment didn't affect clinical response of chemotherapy. (C) 2017 JTCM. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [1] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    Journal of Traditional Chinese Medicine, 2017, 37 (01) : 35 - 42
  • [2] Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
    Xu, Jian-Ming
    Wang, Yan
    Ge, Fei-Jiao
    Lin, Li
    Liu, Ze-Yuan
    Sharma, Manish R.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (24) : 3899 - 3903
  • [3] Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
    Jian-Ming Xu
    Yan Wang
    Fei-Jiao Ge
    Li Lin
    Ze-Yuan Liu
    Manish R Sharma
    World Journal of Gastroenterology, 2013, 19 (24) : 3899 - 3903
  • [4] UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
    Yang, Yuwei
    Zhou, MengMeng
    Hu, Mingjun
    Cui, Yanjie
    Zhong, Qi
    Liang, Ling
    Huang, Fen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e479 - e489
  • [5] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [6] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Fei-fei Han
    Chang-long Guo
    Dan Yu
    Jin Zhu
    Li-li Gong
    Guang-run Li
    Ya-li Lv
    He Liu
    Guang-yu An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 779 - 788
  • [7] UGT1A1☆6 AND UGT1A1☆28 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE LEUKOPENIA IN JAPANESE PATIENTS WITH LUNG CANCER
    Fukuda, Minoru
    Okumura, Manabu
    Hisatomi, Keiko
    Suyama, Naofumi
    Iwakiri, Tomomi
    Takagi, Akinori
    Nakamura, Yoichi
    Arimori, Kazuhiko
    Kohno, Shigeru
    RESPIROLOGY, 2010, 15 : 37 - 37
  • [8] The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
    Chen, Yi-Jing
    Hu, Fei
    Li, Chun-Yan
    Fang, Jue-Min
    Chu, Li
    Zhang, Xi
    Xu, Qing
    BIOMARKERS, 2014, 19 (01) : 56 - 62
  • [9] UGT1A1*28 polymorphism is not associated to irinotecan-induced toxicity in pediatric patients
    de Torres, C.
    Cruz, O.
    Parareda, A.
    Segura, S.
    Mora, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 96 - 96
  • [10] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165